ロード中...
Clinical and comparative utility of afatinib in non-small cell lung cancer
The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. However, all patients deve...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4003149/ https://ncbi.nlm.nih.gov/pubmed/24790411 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S40567 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|